It was proposed that TopoII expression is lower in GRP78-overexpressing cells [37]; thus, it was possible that the myofibroblasts induced by lung cancer cells exhibited a decreased TopoII expression, resulting in the development of resistance to VP-16. The gene discussed is HSPA5; the disease is lung carcinoma.